Nielsen 2026 - Dapiglutide Proof-of-Concept Trial for Obesity

The Lancet Diabetes & Endocrinology·January 1, 2026

C. K. Nielsen

Summary

Human obesity proof-of-concept study evaluating dapiglutide, a dual GLP-1 and GLP-2 receptor agonist.

Study Details

Study Design

Randomized, double-blind, placebo-controlled, parallel-group proof-of-concept trial

Indication

Obesity

Intervention

Once-weekly dapiglutide vs placebo

Species

Human

Risk of Bias Assessment

Early proof-of-concept trial; pipeline status should be tracked separately